Cost of moderate to severe plaque psoriasis in Germany: a multicenter cost-of-illness study.
Standard
Cost of moderate to severe plaque psoriasis in Germany: a multicenter cost-of-illness study. / Sohn, S; Schoeffski, O; Prinz, J; Reich, K; Schubert, E; Waldorf, K; Augustin, Matthias.
In: DERMATOLOGY, Vol. 212, No. 2, 2, 2006, p. 137-144.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Cost of moderate to severe plaque psoriasis in Germany: a multicenter cost-of-illness study.
AU - Sohn, S
AU - Schoeffski, O
AU - Prinz, J
AU - Reich, K
AU - Schubert, E
AU - Waldorf, K
AU - Augustin, Matthias
PY - 2006
Y1 - 2006
N2 - BACKGROUND: There is little information concerning the costs of psoriasis and patients' quality of life (QoL) in Germany. OBJECTIVE: To obtain data on the annual costs and QoL(to follow in a further publication) of patients with moderate to severe plaque psoriasis. METHODS: Between October 2003 and February 2004, six office-based dermatologists and eight dermatology outpatient departments retrospectively documented cost-of-illness data from a societal cost perspective in 184 patients over a 12-month period. Patients were stratified into three subgroups according to their treatment scheme. RESULTS: Mean total costs amounted to euro 6,709 per patient and year. The mean PASI score was 18.2 and PBSA 28.9%. Annual costs were highest with euro 8,831 in high-need patients. They also showed the highest PASI score (22.2). CONCLUSION: Moderate to severe plaque psoriasis is associated with tremendous costs, particularly in patients not adequately controlled by conventional therapies, while the outcomes of patients were unsatisfactory.
AB - BACKGROUND: There is little information concerning the costs of psoriasis and patients' quality of life (QoL) in Germany. OBJECTIVE: To obtain data on the annual costs and QoL(to follow in a further publication) of patients with moderate to severe plaque psoriasis. METHODS: Between October 2003 and February 2004, six office-based dermatologists and eight dermatology outpatient departments retrospectively documented cost-of-illness data from a societal cost perspective in 184 patients over a 12-month period. Patients were stratified into three subgroups according to their treatment scheme. RESULTS: Mean total costs amounted to euro 6,709 per patient and year. The mean PASI score was 18.2 and PBSA 28.9%. Annual costs were highest with euro 8,831 in high-need patients. They also showed the highest PASI score (22.2). CONCLUSION: Moderate to severe plaque psoriasis is associated with tremendous costs, particularly in patients not adequately controlled by conventional therapies, while the outcomes of patients were unsatisfactory.
M3 - SCORING: Zeitschriftenaufsatz
VL - 212
SP - 137
EP - 144
JO - DERMATOLOGY
JF - DERMATOLOGY
SN - 1018-8665
IS - 2
M1 - 2
ER -
